Aytu Biopharma (AYTU)
Aytu Biopharma on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
329K
Short interest
settlement 2026-10-15
14.0
Days to cover
+9.2 days vs prior
31.5%
Short share of volume
2026-11-03
592
Fails to deliver
settlement 2026-10-14
Thu 12 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in AYTU is 328,872 shares, up 17,265 shares over the last month. Over the last 48 readings it ranged from 114,687 shares (14 March 2025) to 740,353 shares (15 May 2025). At the reported average volume of 24K shares a day that is 14.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/aytu" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 328,872 | -4.7% | 23,559 | 13.96 |
| 2026-09-30 | 345,229 | +10.8% | 72,778 | 4.74 |
| 2026-09-15 | 311,607 | -6.8% | 24,193 | 12.88 |
| 2026-08-31 | 334,399 | +4.0% | 27,080 | 12.35 |
| 2026-08-14 | 321,535 | -1.4% | 32,912 | 9.77 |
| 2026-07-31 | 326,227 | -6.0% | 26,109 | 12.49 |
| 2026-07-15 | 347,011 | -0.4% | 21,984 | 15.78 |
| 2026-06-30 | 348,497 | -1.6% | 29,148 | 11.96 |
| 2026-06-15 | 354,360 | -13.1% | 29,116 | 12.17 |
| 2026-05-29 | 407,982 | -10.9% | 46,825 | 8.71 |
| 2026-05-15 | 457,791 | -9.4% | 64,114 | 7.14 |
| 2026-04-30 | 505,368 | +0.6% | 25,601 | 19.74 |
| 2026-04-15 | 502,212 | -0.2% | 36,929 | 13.60 |
| 2026-03-31 | 503,361 | -0.9% | 50,667 | 9.93 |
| 2026-03-13 | 507,879 | +7.8% | 43,555 | 11.66 |
| 2026-02-27 | 471,283 | +3.9% | 39,712 | 11.87 |
| 2026-02-13 | 453,509 | -17.3% | 78,178 | 5.80 |
| 2026-01-30 | 548,197 | +1.0% | 84,363 | 6.50 |
| 2026-01-15 | 542,708 | +5.8% | 164,018 | 3.31 |
| 2025-12-31 | 513,218 | +10.9% | 132,956 | 3.86 |
| 2025-12-15 | 462,866 | +1.2% | 57,898 | 7.99 |
| 2025-11-28 | 457,210 | -6.2% | 49,496 | 9.24 |
| 2025-11-14 | 487,373 | -2.5% | 62,874 | 7.75 |
| 2025-10-31 | 499,690 | -18.4% | 81,848 | 6.11 |
| 2025-10-15 | 612,597 | +1.4% | 263,310 | 2.33 |
| 2025-09-30 | 604,226 | +30.8% | 502,841 | 1.20 |
| 2025-09-15 | 461,813 | -0.6% | 78,467 | 5.89 |
| 2025-08-29 | 464,467 | -1.3% | 78,006 | 5.95 |
| 2025-08-15 | 470,766 | -19.6% | 121,919 | 3.86 |
| 2025-07-31 | 585,164 | +11.0% | 166,955 | 3.50 |
| 2025-07-15 | 527,048 | +7.0% | 141,061 | 3.74 |
| 2025-06-30 | 492,409 | -21.2% | 252,583 | 1.95 |
| 2025-06-13 | 624,633 | +49.9% | 1,065,915 | 1.00 |
| 2025-05-30 | 416,688 | -43.7% | 578,603 | 1.00 |
| 2025-05-15 | 740,353 | +445.3% | 6,178,212 | 1.00 |
| 2025-04-30 | 135,760 | +14.4% | 28,904 | 4.70 |
| 2025-04-15 | 118,651 | +1.1% | 35,008 | 3.39 |
| 2025-03-31 | 117,335 | +2.3% | 36,918 | 3.18 |
| 2025-03-14 | 114,687 | -4.7% | 39,104 | 2.93 |
| 2025-02-28 | 120,364 | -2.8% | 47,073 | 2.56 |
| 2025-02-14 | 123,850 | -3.0% | 31,943 | 3.88 |
| 2025-01-31 | 127,719 | -2.9% | 18,990 | 6.73 |
| 2025-01-15 | 131,571 | -4.2% | 25,367 | 5.19 |
| 2024-12-31 | 137,325 | +8.3% | 26,603 | 5.16 |
| 2024-12-13 | 126,836 | +7.1% | 45,471 | 2.79 |
| 2024-11-29 | 118,397 | -2.0% | 33,212 | 3.56 |
| 2024-11-15 | 120,797 | -37.3% | 61,184 | 1.97 |
| 2024-10-31 | 192,761 | -14.4% | 17,530 | 11.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of AYTU volume is 31.5%, up 21.4 points over the last five sessions. Over the last 30 readings it ranged from 5.0% (20 October 2026) to 80.0% (8 October 2026). The latest reading is 6.1 points below the 30-session average of 37.6%, on 4K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 1K | 4K | 31.5% | 0 |
| 2026-11-02 | 1K | 2K | 58.7% | 0 |
| 2026-10-30 | 7K | 38K | 17.5% | 0 |
| 2026-10-29 | 2K | 3K | 63.3% | 0 |
| 2026-10-28 | 5K | 13K | 38.9% | 0 |
| 2026-10-27 | 2K | 16K | 10.1% | 0 |
| 2026-10-26 | 2K | 10K | 23.1% | 0 |
| 2026-10-23 | 2K | 20K | 12.1% | 0 |
| 2026-10-22 | 2K | 14K | 14.4% | 0 |
| 2026-10-21 | 2K | 3K | 73.5% | 0 |
| 2026-10-20 | 235 | 5K | 5.0% | 0 |
| 2026-10-19 | 2K | 7K | 33.9% | 0 |
| 2026-10-16 | 2K | 10K | 16.4% | 0 |
| 2026-10-15 | 13K | 18K | 74.8% | 0 |
| 2026-10-14 | 3K | 12K | 28.0% | 0 |
| 2026-10-13 | 3K | 12K | 27.8% | 14 |
| 2026-10-12 | 1K | 9K | 11.1% | 0 |
| 2026-10-09 | 5K | 7K | 63.6% | 0 |
| 2026-10-08 | 2K | 3K | 80.0% | 0 |
| 2026-10-07 | 3K | 4K | 77.5% | 0 |
| 2026-10-06 | 1K | 14K | 9.0% | 0 |
| 2026-10-05 | 24K | 36K | 66.2% | 0 |
| 2026-10-02 | 4K | 7K | 55.9% | 0 |
| 2026-10-01 | 4K | 12K | 31.5% | 0 |
| 2026-09-30 | 9K | 36K | 23.9% | 0 |
| 2026-09-29 | 2K | 17K | 13.8% | 0 |
| 2026-09-28 | 2K | 5K | 41.1% | 0 |
| 2026-09-25 | 3K | 10K | 31.6% | 0 |
| 2026-09-24 | 13K | 28K | 46.3% | 0 |
| 2026-09-23 | 53K | 113K | 46.7% | 9 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in AYTU is 592 shares, up 260 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (13 August 2026) to 12,426 shares (23 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 592 | $1.99 | $1K |
| 2026-10-13 | 332 | $1.97 | $654 |
| 2026-10-09 | 1,555 | $2.05 | $3K |
| 2026-10-02 | 1,450 | $2.09 | $3K |
| 2026-10-01 | 1,623 | $2.14 | $3K |
| 2026-09-24 | 341 | $2.28 | $777 |
| 2026-09-23 | 12,426 | $2.23 | $28K |
| 2026-09-22 | 1,138 | $2.13 | $2K |
| 2026-09-17 | 924 | $1.97 | $2K |
| 2026-09-15 | 219 | $2.00 | $438 |
| 2026-09-04 | 668 | $2.29 | $2K |
| 2026-09-03 | 688 | $2.28 | $2K |
| 2026-09-02 | 782 | $2.25 | $2K |
| 2026-09-01 | 22 | $2.29 | $50 |
| 2026-08-26 | 531 | $2.35 | $1K |
| 2026-08-25 | 297 | $2.31 | $686 |
| 2026-08-24 | 1,135 | $2.37 | $3K |
| 2026-08-21 | 778 | $2.28 | $2K |
| 2026-08-20 | 786 | $2.36 | $2K |
| 2026-08-13 | 1 | $2.38 | $2 |
| 2026-08-07 | 75 | $2.33 | $175 |
| 2026-08-05 | 813 | $2.21 | $2K |
| 2026-08-04 | 296 | $2.25 | $666 |
| 2026-07-30 | 2,314 | $2.08 | $5K |
| 2026-07-22 | 572 | $2.18 | $1K |
| 2026-07-20 | 784 | $2.17 | $2K |
| 2026-07-13 | 2,094 | $2.25 | $5K |
| 2026-07-09 | 1,084 | $2.18 | $2K |
| 2026-06-24 | 693 | $2.25 | $2K |
| 2026-06-23 | 323 | $2.25 | $727 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for AYTU in the last 90 days. The most recent filings are listed below. Latest filing: Disbrow Joshua R. (Chief Executive Officer) on 2026-07-28.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-28 | Disbrow Joshua R. | Chief Executive Officer | Grant | 30K | $0.00 | $0 | 237K |
| 2026-07-28 | PYSZCZYMUKA GREG | Chief Commercial Officer | Grant | 20K | $0.00 | $0 | 56K |
| 2026-07-28 | Disbrow Jarrett | Chief Business Officer | Grant | 15K | $0.00 | $0 | 77K |
| 2026-07-28 | Selhorn Ryan J | Chief Financial Officer | Grant | 25K | $0.00 | $0 | 75K |
| 2026-07-28 | LIU VIVIAN H | Director | Grant | 10K | $0.00 | $0 | 30K |
| 2026-07-28 | JAIN ABHINAV | Director | Grant | 10K | $0.00 | $0 | 30K |
| 2026-07-28 | DOCKERY CARL | Director | Grant | 10K | $0.00 | $0 | 31K |
| 2026-07-28 | Donofrio John Jr. | Director | Grant | 10K | $0.00 | $0 | 24K |
| 2025-10-03 | PYSZCZYMUKA GREG | Chief Commercial Officer | Grant | 13K | $0.00 | $0 | 36K |
| 2025-10-03 | Disbrow Jarrett | Chief Business Officer | Grant | 13K | $0.00 | $0 | 62K |
| 2025-10-03 | Disbrow Jarrett | Chief Business Officer | Grant | 20K | $0.00 | $0 | 49K |
| 2025-10-03 | Selhorn Ryan J | Chief Financial Officer | Grant | 18K | $0.00 | $0 | 50K |
| 2025-10-03 | Selhorn Ryan J | Chief Financial Officer | Grant | 16K | $0.00 | $0 | 32K |
| 2025-10-03 | Disbrow Joshua R. | Chief Executive Officer | Grant | 23K | $0.00 | $0 | 207K |
| 2025-10-03 | Disbrow Joshua R. | Chief Executive Officer | Grant | 31K | $0.00 | $0 | 185K |
| 2025-10-03 | LIU VIVIAN H | Director | Grant | 10K | $0.00 | $0 | 20K |
| 2025-10-03 | JAIN ABHINAV | Director | Grant | 10K | $0.00 | $0 | 20K |
| 2025-10-03 | DOCKERY CARL | Director | Grant | 10K | $0.00 | $0 | 20K |
| 2025-10-03 | Donofrio John Jr. | Director | Grant | 10K | $0.00 | $0 | 14K |
| 2025-06-09 | Disbrow Joshua R. | Chief Executive Officer | Buy | 67K | $1.50 | $100K | 153K |
| 2025-06-09 | Disbrow Jarrett | Chief Business Officer | Buy | 17K | $1.50 | $25K | 29K |
| 2025-03-31 | PYSZCZYMUKA GREG | Chief Commercial Officer | Exercise or conversion | 209 | price not stated in the filing | not stated | 24K |
| 2025-02-28 | Disbrow Joshua R. | Chief Executive Officer | Buy | 15K | $1.30 | $20K | 87K |
| 2025-02-05 | Selhorn Ryan J | Chief Financial Officer | Exercise or conversion | 105 | price not stated in the filing | not stated | 16K |
| 2024-12-31 | PYSZCZYMUKA GREG | Chief Commercial Officer | Exercise or conversion | 208 | price not stated in the filing | not stated | 23K |
| 2024-11-11 | Selhorn Ryan J | Chief Financial Officer | Grant | 14K | $0.00 | $0 | 16K |
| 2024-11-06 | LIU VIVIAN H | Director | Grant | 2K | $0.00 | $0 | 10K |
| 2024-11-06 | JAIN ABHINAV | Director | Grant | 2K | $0.00 | $0 | 10K |
| 2024-11-06 | Donofrio John Jr. | Director | Grant | 2K | $0.00 | $0 | 4K |
| 2024-11-06 | DOCKERY CARL | Director | Grant | 2K | $0.00 | $0 | 10K |
| 2024-09-30 | PYSZCZYMUKA GREG | Chief Commercial Officer | Exercise or conversion | 209 | price not stated in the filing | not stated | 23K |
| 2024-06-30 | PYSZCZYMUKA GREG | Chief Commercial Officer | Exercise or conversion | 208 | price not stated in the filing | not stated | 23K |
| 2024-03-31 | PYSZCZYMUKA GREG | Chief Commercial Officer | Exercise or conversion | 208 | price not stated in the filing | not stated | 23K |
| 2023-12-31 | PYSZCZYMUKA GREG | Chief Commercial Officer | Exercise or conversion | 209 | price not stated in the filing | not stated | 23K |
| 2023-09-30 | PYSZCZYMUKA GREG | Chief Commercial Officer | Exercise or conversion | 208 | price not stated in the filing | not stated | 22K |
| 2023-08-16 | JAIN ABHINAV | Director | Grant | 7K | $0.00 | $0 | 8K |
| 2023-08-11 | LIU VIVIAN H | Director | Grant | 2K | $0.00 | $0 | 8K |
| 2023-08-11 | DOCKERY CARL | Director | Grant | 2K | $0.00 | $0 | 9K |
| 2023-08-11 | Donofrio John Jr. | Director | Grant | 2K | $0.00 | $0 | 2K |
| 2023-08-11 | LIU VIVIAN H | Director | Grant | 2K | $0.00 | $0 | 2K |
| 2023-08-11 | JAIN ABHINAV | Director | Grant | 2K | $0.00 | $0 | 2K |
| 2023-06-30 | PYSZCZYMUKA GREG | Chief Commerical Officer | Exercise or conversion | 208 | price not stated in the filing | not stated | 22K |
| 2023-06-16 | PYSZCZYMUKA GREG | Chief Commerical Officer | Buy | 12K | $1.87 | $22K | 22K |
| 2023-06-14 | Disbrow Joshua R. | Chief Executive Officer | Buy | 14K | $1.86 | $26K | 72K |
| 2023-04-25 | PYSZCZYMUKA GREG | Chief Commerical Officer | Exercise or conversion | 833 | $0.00 | $0 | 10K |
| 2023-02-08 | LIU VIVIAN H | Director | Grant | 7K | $0.00 | $0 | 7K |
| 2022-12-21 | DOCKERY CARL | Director | Returned to company | 40K | $0.00 | $0 | 149K |
| 2022-12-21 | Cantrell Gary | Director | Returned to company | 40K | $0.00 | $0 | 164K |
| 2022-12-21 | Donofrio John Jr. | Director | Returned to company | 188K | $0.00 | $0 | 15K |
| 2022-12-20 | Disbrow Joshua R. | Chief Executive Officer | Returned to company | 80K | $0.00 | $0 | 1.2M |
| 2022-12-19 | PYSZCZYMUKA GREG | Chief Commercial Officer | Buy | 100K | $0.24 | $24K | 182K |
| 2022-12-19 | Disbrow Joshua R. | Chief Executive Officer | Buy | 112K | $0.22 | $25K | 1.2M |
| 2022-11-18 | Oki Mark K | Chief Financial Officer | Grant | 90K | $0.23 | $21K | 190K |
| 2022-11-18 | Disbrow Joshua R. | Chief Executive Officer | Grant | 222K | $0.24 | $53K | 1.1M |
| 2022-11-18 | Oki Mark K | Chief Financial Officer | Buy | 90K | $0.23 | $21K | 190K |
| 2022-11-18 | Disbrow Joshua R. | Chief Executive Officer | Buy | 222K | $0.24 | $53K | 1.1M |
| 2022-07-01 | LIU VIVIAN H | Director | Grant | 7K | $0.00 | $0 | 7K |
| 2022-01-17 | Oki Mark K | Chief Financial Officer | Grant | 100K | $0.00 | $0 | 100K |
| 2021-04-16 | Disbrow Joshua R. | Chief Executive Officer | Grant | 800K | $0.00 | $0 | 898K |
| 2021-04-16 | Cantrell Gary | Director | Grant | 188K | $0.00 | $0 | 204K |
| 2021-04-16 | Donofrio John Jr. | Director | Grant | 188K | $0.00 | $0 | 203K |
| 2021-04-16 | MACALUSO MICHAEL | Director | Grant | 188K | $0.00 | $0 | 208K |
| 2021-04-16 | DOCKERY CARL | Director | Grant | 188K | $0.00 | $0 | 189K |
| 2021-04-08 | Hecht Beth | Director | Grant | 7K | $0.00 | $0 | 9K |
| 2021-04-08 | McLaughlin Gerald W. | Director | Grant | 7K | $0.00 | $0 | 31K |
| 2021-03-31 | Eisenstadt Richard I | Chief Financial Officer | Grant | 55K | $0.00 | $0 | 69K |
| 2021-03-29 | Armistice Capital Master Fund Ltd. | Director | Other transaction | 2K | $0.00 | $0 | 1.3M |
| 2021-03-29 | Armistice Capital Master Fund Ltd. | Director | Other transaction | 0 | $0.00 | $0 | 1.3M |
| 2021-03-20 | Armistice Capital Master Fund Ltd. | Director | Other transaction | 0 | $0.00 | $0 | 1.3M |
| 2021-03-20 | Armistice Capital Master Fund Ltd. | Director | Other transaction | 7K | $0.00 | $0 | 1.3M |
| 2020-12-11 | Armistice Capital Master Fund Ltd. | Director | Buy | 0 | $0.00 | $0 | 1.3M |
| 2020-12-11 | Armistice Capital Master Fund Ltd. | Director | Buy | 1.3M | $6.00 | $8.0M | 1.3M |
| 2020-06-08 | Cantrell Gary | Director | Grant | 10K | price not stated in the filing | not stated | 163K |
| 2020-06-08 | Disbrow Joshua R. | Chief Executive Officer | Grant | 450K | price not stated in the filing | not stated | 975K |
| 2020-06-08 | Green David A | Chief Financial Officer | Grant | 250K | price not stated in the filing | not stated | 521K |
| 2020-04-27 | Boyd Steven | Director | Exercise or conversion | 0 | $0.00 | $0 | 5.1M |
| 2020-04-27 | Boyd Steven | Director | Sell | 0 | $0.00 | $0 | 0 |
| 2020-04-27 | Boyd Steven | Director | Sell | 5.1M | $1.82 | $9.3M | 0 |
| 2020-04-27 | Boyd Steven | Director | Exercise or conversion | 5.0M | $1.25 | $6.3M | 5.1M |
| 2020-04-15 | Cerecor Inc. | TenPercentOwner | Sell | 93K | $1.55 | $144K | 9.7M |
| 2020-04-10 | Cerecor Inc. | TenPercentOwner | Conversion | 9.8M | price not stated in the filing | not stated | 9.8M |
| 2020-04-06 | Boyd Steven | Director | Other transaction | 0 | $0.00 | $0 | 109K |
| 2020-04-06 | Boyd Steven | Director | Other transaction | 109K | $0.00 | $0 | 109K |
| 2020-03-10 | Boyd Steven | Director | Exercise or conversion | 5.0M | $1.00 | $5.0M | 15.2M |
| 2020-03-10 | Boyd Steven | Director | Exercise or conversion | 1.9M | price not stated in the filing | not stated | 10.2M |
| 2020-03-10 | Boyd Steven | Director | Sell | 2.5M | $0.99 | $2.4M | 1 |
| 2020-03-10 | Boyd Steven | Director | Sell | 0 | $0.00 | $0 | 2.5M |
| 2020-03-10 | Boyd Steven | Director | Sell | 19.6M | $1.47 | $28.8M | 2.5M |
| 2020-03-10 | Boyd Steven | Director | Exercise or conversion | 3.9M | $1.50 | $5.9M | 22.0M |
| 2020-03-10 | Boyd Steven | Director | Tax withholding | 0 | $0.00 | $0 | 18.1M |
| 2020-03-10 | Boyd Steven | Director | Tax withholding | 1.5M | $1.30 | $1.9M | 18.1M |
| 2020-03-10 | Boyd Steven | Director | Exercise or conversion | 0 | $0.00 | $0 | 19.6M |
| 2020-03-10 | Boyd Steven | Director | Exercise or conversion | 4.4M | $1.00 | $4.4M | 19.6M |
| 2020-02-14 | Boyd Steven | Director,TenPercentOwner | Other transaction | 0 | $0.00 | $0 | 8.3M |
| 2020-02-14 | Boyd Steven | Director,TenPercentOwner | Other transaction | 335K | price not stated in the filing | not stated | 8.3M |
| 2020-01-21 | Mehta Ketan Bhupatrai | Director | Grant | 10K | price not stated in the filing | not stated | 75K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of AYTU in its latest filing, on Schedule 13G (passive). The holder is AWM Investment Company, Inc. at 5.8% of the class (619,574 shares), filed 2026-02-13 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 3 | LYTTON LAURENCE Windividual | 546K | 5.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | LYTTON-KAMBARA FOUNDATIONindividual | 546K | 5.0% | 2026-06-30 |
| 2026-02-13 | 13G/Ano. 1 | AWM Investment Company, Inc.investment adviser | 620K | 5.8% | 2025-12-31 |
| 2025-11-12 | 13G/Ano. 1 | Philotimo Fund, LPpartnership | 0 | 0.0% | 2025-09-30 |
| 2025-11-12 | 13G/Ano. 1 | Philotimo Focused Growth & Income Fundother entity | 0 | 0.0% | 2025-09-30 |
| 2025-11-12 | 13G/Ano. 1 | Kanen Wealth Management LLCinvestment adviser | 0 | 0.0% | 2025-09-30 |
| 2025-11-12 | 13G/Ano. 1 | Kanen Davidindividual | 0 | 0.0% | 2025-09-30 |
13F holders
Tracked managers holding AYTU at their latest 13F. JSON3 of the 30 tracked managers held AYTU at their latest 13F, $558K in total at quarter-end prices. Two Sigma Investments is the largest at $226K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 105K | $226K | 0.00% | -17K |
| Renaissance Technologies | 2026-06-30 | 105K | $225K | 0.00% | +11K |
| Citadel Advisors | 2026-06-30 | 49K | $106K | 0.00% | +13K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Aytu Biopharma in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Aytu Biopharma (AYTU), SEC CIK 1385818, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-09-22.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-28.JSON and CSV
- Company record
- EDGAR filing index for CIK 1385818Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of AYTU is sold short?
328,872 shares were held short at the 2026-10-15 settlement, 14.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is AYTU's daily short volume?
On 2026-11-03, 1,125 of the 3,575 AYTU shares reported to FINRA were sold short, 31.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does AYTU have fails to deliver?
The SEC's latest file shows 592 AYTU shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are AYTU insiders buying or selling?
No open-market insider trades were reported for AYTU in the last 90 days. The most recent filings are listed below. Latest filing: Disbrow Joshua R. (Chief Executive Officer) on 2026-07-28.
Who owns 5% or more of AYTU?
1 holder reports 5% or more of AYTU in its latest filing, on Schedule 13G (passive). The holder is AWM Investment Company, Inc. at 5.8% of the class (619,574 shares), filed 2026-02-13 for an event on 2025-12-31.
Which tracked 13F managers own AYTU?
3 of the 30 tracked 13F managers held AYTU shares at their latest filing, $558K in all. The largest: Two Sigma Investments (105K shares, $226K), Renaissance Technologies (105K shares, $225K), Ken Griffin's Citadel Advisors (49K shares, $106K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.